Servier pairs with Nerviano on TTK-targeting cancer program
This article was originally published in Scrip
The French pharma company Servier has signed an R&D collaboration and worldwide license agreement with Nerviano Medical Sciences, an Italian oncology-focused R&D company owned by the region of Lombardy. The deal is for first-in-class Nerviano compounds inhibiting the protein kinase TTK/MPS1.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.